Research Radar

What it is

Not a summary of the news. Two computed signals, run monthly against the full Agewell Brief archive:

• Evidence maturation — which frontier vectors climbed from speculative or emerging toward contested or established, with a real gap in time between the two findings. Same-day variance across two takes on one topic doesn't count; this is about mechanisms genuinely gaining independent support over months.
• Cross-framework convergence — historical antecedents independently cited by briefs in unrelated categories, surfacing which underlying mechanisms disparate current research is converging on without being told to look for it.

Every entry links to the specific, dated brief that produced it. Nothing is inferred without a citation you can open and check yourself.

Who this is for

• Longevity biotech investors who want an early, falsifiable signal on which mechanisms are gaining real support, not just press coverage.
• R&D teams at supplement and longevity brands scanning for where the science is actually moving before committing formulation budget.
• Analysts who want a sourced starting point for diligence, not a black-box AI summary.

How it works

One issue a month, delivered by email. Each issue covers what moved since the last one — new maturation climbs, new convergence hits — plus a running methodology note so you always know exactly what's being measured and why. Monthly rather than weekly on purpose: a thin week padded to hit a schedule is worse than no issue at all, and every finding here has to be a real evidence-position climb or a real citation convergence computed from the archive — never a summary written to fill space.

Price

$399/month, or $3,990/year. No trial, no self-serve checkout yet — every subscription starts as a conversation so the first issue actually reflects what you're trying to track.